Cagrilintide vs GLP-1: what to do if semaglutide, tirzepatide, and retatrutide all failed

Semaglutide, tirzepatide, and retatrutide are not three different drugs. They're one receptor with more attachments bolted on. Semaglutide hits GLP-1 alone, tirzepatide adds GIP, retatrutide adds glucagon on top of that. If the problem is GLP-1 activation itself, cycling through all three is cycling through the same core mechanism with extra features. That's the gap nobody names for people who got sick on all of them: there's no approved, standalone alternative outside the GLP-1 receptor.

What "I failed all three" usually means

Before writing off the class, it's worth separating two different failures.

Dose-too-fast failure. Standard semaglutide titration starts at 0.25 mg and ramps to ~2.5 mg over 16 weeks. Skipping that ramp is a known way to get violently sick: roughly 1 mg from an unreliable source, taken without titrating, has been reported to cause projectile vomiting through a full night. Clinicians who work with these drugs describe most of the severe GI reactions they see as a dosing problem, not a drug problem, though that's a clinical opinion, not a controlled trial finding.

Class-level intolerance. A smaller group titrates correctly and still can't hold any dose without nausea, vomiting, or GI distress bad enough to stop. Nausea rates differ by molecule (tirzepatide runs 25-33% at top dose, retatrutide 40-45%), and retatrutide adds dysesthesia, a tingling skin sensation, in roughly 1 in 8 to 1 in 5 patients at 12 mg. So even within the class, tolerability isn't uniform. But if a slow, correct titration on more than one of these drugs still produces intolerable side effects, the receptor itself is probably the issue, not the ramp speed.

This distinction matters for the real-world numbers too. Roughly half of GLP-1 users in a Danish cohort study discontinued within a year; a US analysis of over 125,000 patients found 46.5% of diabetic and 64.8% of non-diabetic users off the drug at 12 months, with only about 14% still on Wegovy at three years. Some of that is tolerability, some is cost, some is the support layer around the prescription. The dropout rate alone doesn't tell you which one you're dealing with.

Cagrilintide doesn't touch the GLP-1 receptor, but check the fine print

Cagrilintide works on the amylin pathway, a separate appetite-signaling system from GLP-1. Mechanistically, this is the real non-GLP-1 candidate people are pointing to when they ask about alternatives.

Here's the catch: the phase 2/3 data behind cagrilintide is for CagriSema, the combination product that pairs cagrilintide with semaglutide. That data supports the combo, not cagrilintide as a standalone drug for someone who can't tolerate GLP-1 activation at all. If GLP-1 itself made you sick, a product that still contains semaglutide isn't a clean escape route. It's a lower relative GLP-1 exposure, not an absence of it. Evidence tier here is moderate: real trial data exists, but for the combination, not for the thing most people asking this question actually want.

What's actually true right now

• No approved monotherapy exists for someone who wants amylin-pathway appetite suppression without any GLP-1 exposure.
• The evidence base for cagrilintide is combination-only. Anyone offering cagrilintide alone, especially compounded, is working outside the trial data that exists for it.
• Dropout is common and multi-causal. A high real-world discontinuation rate on GLP-1s doesn't by itself prove you have a class-level intolerance versus a titration, cost, or support problem.

None of this is a reason to self-diagnose or self-source. If you've genuinely failed a correct titration on more than one GLP-1 agonist, that's a conversation for a clinician who can review your specific reactions and decide whether amylin-pathway options, correctly dosed and monitored, make sense for you. It is not a green light to order a compounded cagrilintide vial off a random storefront and hope the label matches the vial. If you're evaluating any source for a peptide outside the approved-drug channel, run it through how to vet a peptide seller before it goes anywhere near a syringe.

For more on why GLP-1 tolerability varies by drug and dose, see why starting two GLP-1s at once makes you too sick to eat and the peptide stack your clinic prescribed came without a dosing protocol. More on the metabolic category at the Ouros Lab blog.

FAQ

Is cagrilintide a GLP-1 drug?

No. It targets the amylin pathway, a separate appetite-signaling system. Semaglutide, tirzepatide, and retatrutide all activate the GLP-1 receptor; cagrilintide doesn't.

Can I get cagrilintide without semaglutide?

The phase 2/3 data that exists is for CagriSema, the cagrilintide-plus-semaglutide combination. A standalone cagrilintide product isn't backed by the same trial evidence. Anyone offering it alone is operating outside that data, and that's a question to bring to a clinician, not a vendor.

I got sick on semaglutide, tirzepatide, and retatrutide. Does that mean I can't use any GLP-1?

It depends on whether each attempt used a correct, slow titration. A rushed ramp can cause severe GI symptoms that look like intolerance but are actually a dosing error. If you titrated correctly on more than one and still couldn't hold a dose, that pattern is worth bringing to a clinician as a possible class-level reaction.

What should I actually do if none of the approved GLP-1s work for me?

Talk to a clinician about what specifically happened on each attempt, at what dose, on what timeline. There's no self-directed protocol for GLP-1 class intolerance right now, and no approved amylin-only drug to swap in. Anything outside that conversation is unverified.